Table 2.
Outcome of minor or chronic irAEs
| Study | Rheumatic or neuromuscular irAEs (n) | Outcome | Treatment of irAEs | IrAE response to treatment |
|---|---|---|---|---|
| Ascierto 2014 [23] | Vasculitis (1) | Therapy discontinued (1) | Therapy discontinued (1) | NA |
| Cortellini 2019 [24] | Rheumatologic, neuromuscular |
OS HR 0.61 [0.38–0.97], P = 0.04 PFS HR 0.84 [0.57–1.23], P = 0.37 |
NA | NA |
| Grangeon 2018 [26] | Arthralgia (5), psoriasis (1) | NA | NA | NA |
| Horvat 2015 [28] | Uveitis (8) | Therapy discontinued (1) |
Systemic corticosteroids (1), therapy discontinued (1) |
Improved |
| Neurotoxicity (1) | Therapy discontinued (1) | Therapy discontinued (1) | NA | |
| Arthritis (1) | NA | Systemic corticosteroids (1) | Improved | |
| Haratani 2017 [27] | Polyarthritis (1), myasthenia gravis (1) | NA | NA | NA |
|
Indini 2018 [29] |
Arthralgias (11), myasthenia with myositis (1), headache (2), paresthesia (2), peripheral sensory neuropathy (8), peripheral motor neuropathy (1), uveitis (1) | NA | NA | NA |
| Kawai 2019 [30] | Myasthenia gravis (1) | NA | NA | NA |
| Masuda 2019 [31] | Myalgia (1), peripheral motor neuropathy (1) | NA | NA | NA |
| Okamoto 2019 [33] | Myositis (1), rheumatoid arthritis (1) | NA | NA | NA |
| Ricciuti 2018 [34] | Uveitis (1), arthritis (7), polymyalgia rheumatica (1), dermatomyositis (1) | NA | NA | NA |
| Rogado 2019 [35] | Arthritis (3) | Therapy discontinued (1) | Therapy discontinued (1) | NA |
| Myositis (1) | NA | NA | NA | |
| Shafqat 2018 [37] | Arthralgia/arthritis (9) | NA | Prednisone (5) | NA |
| Study | Rheumatic or neuromuscular irAEs (n) | Outcome | Treatment of irAEs | IrAE response to treatment |
| Toi 2018 [39] | Myositis or peripheral neuropathy (5) | PR (4), SD (1) | NA | NA |
| Rheumatoid factor positive |
PFS HR 0.61 [0.38–0.97], P = 0.04 |
NA | NA | |
| Bjornhart 2019 [42] | Arthritis (24) |
OS HR 0.35 [0.11–1.12], P = 0.08 PFS HR 0.51 [0.22–1.17], P = 0.11 |
NA | NA |
| Uveitis, myositis | NA | NA | NA | |
| Ksienski 2018 [47] | Arthralgias (8) (caused by nivolumab) |
OS (month) NR (8.27-NR) vs 10.1 (8.3–14.2), P = 0.44 |
NA | NA |
| Arthralgias (5) (caused by pembrolizumab) |
OS (month) NR (NR-NR) vs 13.5 (10.6-NR), P = 0.42 |
NA | NA | |
| Neurologic (3), myopathy (2), myositis (1), polymyalgia rheumatica (1), vasculitis (1) | NA | NA | NA | |
| Lisberg 2018 [49] | Joint pain (2) | NA | NA | NA |
| Sugano 2020 [56] | Ocular myasthenia gravis (1) | NA | NA | NA |
| Maher 2019 [50] | Musculoskeletal pain, rhabdomyolysis, Muscle spasms | NA | NA | NA |
| Hua 2016 [16] | Arthralgia (11) | NA | NA | NA |
| Lesueur 2018 [48] | Rheumatological (6) | NA | NA | NA |
| Nakamura 2017 [17] | Psoriasis (1) | Therapy discontinued (1) | NA | NA |
| Weber 2017 [58] | Arthralgia (39) | NA | NA | NA |
| Yamazaki 2017 [59] | Arthralgia (3) | NA | NA | NA |
NA not available, NR not reached